Gemini Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Boston MA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT04246866
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Gemini Therapeutics, Inc.